【are texas roadhouse peanuts free】More drugmakers hike U.S. prices as new year begins
By Michael Erman
NEW YORK (Reuters) - Drugmakers including Bristol-Myers Squibb Co
Reuters reported on Tuesday that drugmakers including Pfizer Inc
Nearly all of the price increases are below 10% and the median price increase is around 5%, according to 3 Axis.
More early year price increases could still be announced.
Soaring U.S. prescription drug prices are expected to again be a central issue in the presidential election. President Donald Trump, who made bringing them down a core pledge of his 2016 campaign, is running for re-election in 2020.
Many branded drugmakers have pledged to keep their U.S. list price increases below 10% a year, under pressure from politicians and patients.
The United States, which leaves drug pricing to market competition, has higher prices than in other countries where governments directly or indirectly control the costs, making it the world's most lucrative market for manufacturers.
Drugmakers often negotiate rebates on their list prices in exchange for favorable treatment from healthcare payers. As a result, health insurers and patients rarely pay the full list price of a drug.
Bristol-Myers said in a statement it will not raise list prices on its drugs by more than 6% this year.
The drugmaker raised the price on 10 drugs on Wednesday, including 1.5% price hikes on cancer immunotherapies Opdivo and Yervoy and a 6% increase on its blood thinner Eliquis, all of which bring in billions of dollars in revenue annually.
It also raised the price on Celgene's flagship multiple myeloma drug, Revlimid, 6%. Bristol acquired rival Celgene in a $74 billion deal last year.
Gilead raised prices on more than 15 drugs including HIV treatments Biktarvy and Truvada less than 5%, according to 3 Axis.
Biogen price increases included a 6% price hike on multiple sclerosis treatment Tecfidera, according to 3 Axis.
Gilead and Biogen could not be immediately reached for comment.
3 Axis advises pharmacy industry groups on identifying inefficiencies in the U.S. drug supply chain and has provided consulting work to hedge fund billionaire John Arnold, a prominent critic of high drug prices.
(Reporting by Michael Erman; Editing by Nick Zieminski)
View comments
(责任编辑:Leisure)
- The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FITB, BBBY and IQ
- Donald Trump vows 'major' steps to aid US economy amid coronavirus rise
- Worldwide Artificial Intelligence in Energy Industry to 2024 - Key Drivers, Challenges and Trends
- iRhythm Technologies, Inc. Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?
- Capstar Financial Holdings, Inc. (NASDAQ:CSTR) Passed Our Checks, And It's About To Pay A US$0.05 Dividend
- How to Time the Markets Like an Investing Pro - April 01, 2020
- ServiceNow (NOW) Set to Acquire AI-Focused Startup Element AI
- Customer Data Reveals Shift in Peak Online Shopping Hours
- LeadsRx and WideOrbit Partnership Gives Advertisers Access to Advertising Campaign Data to Maximize ROAS
- What Cineworld Group plc’s (LON:CINE) ROE Can Tell Us
- A Sliding Share Price Has Us Looking At Malibu Boats, Inc.'s (NASDAQ:MBUU) P/E Ratio
- Harpoon Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
- GE Aviation Furloughs Half Its Engine Manufacturing Workforce Amid Coronavirus Pandemic
-
Is Focus Financial Partners (FOCS) a Great Growth Stock?
Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captiva ...[详细] -
Is Husqvarna AB (publ) (STO:HUSQ B) An Attractive Dividend Stock?
Is Husqvarna AB (publ) (STO:HUSQ B) a good dividend stock? How can we tell? Dividend paying companie ...[详细] -
What Kind Of Shareholders Hold The Majority In Select Bancorp, Inc.'s (NASDAQ:SLCT) Shares?
If you want to know who really controls Select Bancorp, Inc. (NASDAQ:SLCT), then you'll have to look ...[详细] -
AUD/USD Forecast: Bottomed At 0.6038, At Risk Of Losing The 0.6000 Level
AUD/USD Current Price: 0.6067Australian and Chinese March manufacturing output beat the market’s exp ...[详细] -
Otter Tail (OTTR) Tops Q3 Earnings and Revenue Estimates
Otter Tail (OTTR) came out with quarterly earnings of $0.87 per share, beating the Zacks Consensus E ...[详细] -
Bill.com Holdings Inc (BILL) President and CEO Rene A. Lacerte Sold $1.2 million of Shares
- By insiderPresident and CEO of Bill.com Holdings Inc (30-Year Financial,Insider Trades)Rene A. Lac ...[详细] -
Is Cobre (ASX:CBE) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, biotec ...[详细] -
Whilst it may not be a huge deal, we thought it was good to see that theOrezone Gold Corporation(CVE ...[详细]
-
Green Stream Highlights Recent Video Presenting Company's Unique Solar Energy Solution
Pacific Palisades, California--(Newsfile Corp. - May 1, 2020) - Green Stream Holdings Inc. (OTC Pink ...[详细] -
How Does Prosperity Bancshares's (NYSE:PB) P/E Compare To Its Industry, After The Share Price Drop?
Unfortunately for some shareholders, theProsperity Bancshares(NYSE:PB) share price has dived 32% in ...[详细]
JPMorgan (JPM) Plans for 20% Rise in 2020-end Trading Bonus
What Is MDU Resources Group's (NYSE:MDU) P/E Ratio After Its Share Price Tanked?
- Did Apogee Enterprises, Inc.'s (NASDAQ:APOG) Recent Earnings Growth Beat The Trend?
- Is Husqvarna AB (publ) (STO:HUSQ B) An Attractive Dividend Stock?
- Patrick Downey Is The President of Orezone Gold Corporation (CVE:ORE) And They Just Spent US$108k On Shares
- Does Credit Card Travel Insurance Cover the Coronavirus?
- Ra Medical Systems, Inc. to Host Earnings Call
- Rackspace Technology Among the First to Support the Launch of Professional Services in AWS Marketplace, Announces New Professional Services & Solutions at AWS re:Invent 2020
- Here's What World Precision Machinery Limited's (SGX:B49) P/E Is Telling Us